One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Spectral Medical Inc.
EDTXF · PNK · Healthcare · Diagnostics & Research
Current price
$0.77
52-week range
$0.64 - $1.10
Market cap
$227.39M
Balance sheet
Distressed
-2.26x Concerning
Net cash $0.00. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
0 Risks
1 rewards · 0 risks
View details ↓What this company does
Spectral Medical Inc.
Spectral Medical Inc. makes medical tests and devices that help doctors treat a life-threatening condition called septic shock by quickly finding and removing a harmful substance from the blood. Their main money comes from selling these innovative products to hospitals and labs around the world, which is important because it helps save lives and gives the company a way to grow.
How the company got here
Spectral Medical Inc. was founded in 1991, originally as Spectral Diagnostics Inc., and is based in Toronto, Canada. The company's journey has been focused on developing innovative solutions for critical medical conditions. A key turning point was its name change to Spectral Medical Inc. in December 2014, signaling a refined focus on its core business areas. The company has since concentrated its efforts on commercializing products aimed at treating septic shock, a life-threatening condition.
What it actually does
Spectral Medical Inc. is dedicated to creating and selling products that help treat septic shock, a severe and dangerous response to infection. Think of it like this: when the body fights an infection, sometimes the fight itself causes widespread damage. Spectral Medical develops tools to help manage this overwhelming response. Their work involves both diagnostic tests to identify problems early and therapeutic devices to treat them directly.
Endotoxin Activity Assay (EAA)
This business line involves a rapid in-vitro diagnostic test (a test done outside the body, in a lab) designed to detect components of gram-negative bacteria. These bacteria are often a cause of serious infections that can lead to septic shock. The EAA test helps doctors quickly identify if these specific bacterial components are present, allowing for faster treatment decisions. This diagnostic tool is a crucial part of Spectral Medical's strategy to combat sepsis early.
Polymyxin B-Hemoperfusion
This is Spectral Medical's therapeutic (treatment-focused) product. It's a hemoperfusion device, which is essentially a specialized filter that cleans the blood. Specifically, this device is designed to remove endotoxins from the bloodstream. Endotoxins are harmful substances released by certain bacteria that can trigger a severe inflammatory response, leading to septic shock. By filtering these toxins out, the device aims to reduce the body's overwhelming reaction and help patients recover.
Antibody and Protein Development
Beyond its direct treatments for septic shock, Spectral Medical also develops, manufactures, and markets specialized biological products. This includes monoclonal and polyclonal antibodies (proteins made by the immune system to fight specific invaders) and recombinant cardiac proteins (proteins related to heart function, often used in research). These products are valuable tools for other companies and researchers in their own research and development efforts, as well as for diagnostic companies that use them to create their own tests.
What management is betting on now
Management at Spectral Medical is primarily focused on the commercialization and wider adoption of its septic shock treatments, particularly the Polymyxin B-Hemoperfusion device. They are strategically expanding their reach in key markets like the United States and Europe. The company is also likely investing in further research and development to refine its existing products and potentially explore new applications for its technologies. Success in these areas is crucial for driving revenue growth and establishing Spectral Medical as a leader in critical care interventions.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $0.77
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net cash $0 - more cash than debt. Interest coverage -2.3x.
Net debt
$0.00
Interest coverage
-2.26x
Distressed
Worse cushion
Baseline
Better cushion
EDTXF
BASELINE
Spectral Medical Inc.
Total debt — Interest coverage -2.26x This is the baseline the peer rows are being compared against.
What you should know
The case for and against EDTXF
1 Reward
0 Risks
Rewards
-
Revenue grew 6.8% last year.
Risks
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
—
P/B
-4.57x
P/S
—
EV/EBITDA
—
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
—
ROA
—
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
—
Quick ratio
—
Total debt
—
Total cash
—
Growth
How the business has been compounding
Revenue TTM
$1.73M
Revenue 5Y CAGR
13.6%
EPS TTM
-0.09
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-6.74M
Free CF TTM
$-6.88M
FCF margin
-398.0%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
2011-12-19